Literature DB >> 35117214

Clinicopathological characteristics and survival outcomes of younger patients with gastric cancer: a systematic review and meta-analysis.

Penghui Niu1, Lulu Zhao1, Rui Ling2, Dongbing Zhao1, Yingtai Chen1.   

Abstract

BACKGROUND: Survival outcomes of gastric cancer in younger patients have been reported in several studies with controversial results. This systematic review and meta-analysis investigated the clinicopathological characteristics, postoperative complications, and survival outcomes between younger and older patients.
METHODS: We systematically reviewed clinical researches from PubMed, The Cochrane Library, Embase, and Web of science published up to December 2019. The effect size for the included studies was estimated with the odds ratio (OR). Heterogeneity was investigated using the χ2 test and I2 test, while sensitivity analyses were performed to identify the source of substantial heterogeneity.
RESULTS: A total of 25 clinical studies involving 81,188 gastric cancer patients were included in this meta-analysis, of which one was a prospective study. Younger patients were more likely to be females, pTNM stage IV and peritoneal metastasis. The incidence of postoperative complications, lymph node metastasis, as well as hepatic metastasis of younger patients was significantly lower than that of the older. There was no statistical difference in overall survival (OS) between the younger and older patients with gastric cancer. After stratification for patients with gastrectomy, however, younger patients were associated with a better 5-year OS relative to older patients.
CONCLUSIONS: In conclusion, younger patients with gastric cancer were more often diagnosed as poorly differentiation and later pTNM tumor stage. However, younger cancer patients following gastrectomy had a better OS rate than patients in older group. Future large-scale analyses are expected to confirm our findings. 2020 Translational Cancer Research. All rights reserved.

Entities:  

Keywords:  Gastric cancer; clinicopathological characteristics; meta-analysis; survival outcomes; younger adult

Year:  2020        PMID: 35117214      PMCID: PMC8797321          DOI: 10.21037/tcr-20-2024

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN: 2218-676X            Impact factor:   1.241


Introduction

Gastric cancer is an aggressive malignancy and remains the third leading cause of cancer-related death worldwide (1,2). Although the overall incidence of gastric cancer showed a decline worldwide, younger cancer patients had increased obviously during the last decades (3). The growing incidence, as well as its aggressive biological behavior as reported (4,5), has renewed interest in the surgery-based management of younger gastric cancer patients with a focus on therapeutic strategies. To date, the survival outcomes of younger patients were still controversial. Previous data reported that younger patients had worse survival rates than older (6-9), whereas several studies showed a similar prognosis (10-20). Some studies even expressed that younger patients were associated with improved survival outcomes (21-30). A significant reason for these inconsistent findings from published studies was the different age cutoffs on defining younger patients (6,7,29,30). A published meta-analysis has reported improved 5-year survival in the younger group. However, it was primarily limited to the small sample size and significant heterogeneity (31). Besides, there was currently no randomized clinical trial that targeted the issue. As such, our study aimed to compare the clinicopathological characteristics, postoperative complications, as well as survival outcomes between younger and older patients with gastric cancer through systematic review and meta-analysis, thus providing evidence for the development of guiding strategies for younger gastric cancer patients. We present the following article in accordance with the PRISMA reporting checklist (available at http://dx.doi.org/10.21037/tcr-20-2024).

Methods

Search strategy

Clinical studies were systematically searched from PubMed, Web of Science, Embase, and The Cochrane Library. The following fields were used for the search: “gastric” or “stomach,” “cancer” or “carcinoma” or “neoplasm” or “tumor,” “young adult” or “younger” or “youth.” These searches were limited to clinical articles published up to December 2019.

Inclusion and exclusion criteria

Studies met the following criteria were included: (I) researches compared gastric cancer in the younger group (≤40 years of age) and older group (>40 years of age); (II) analyses contained quantitative clinicopathological information; (III) researches involved at least one of the mentioned survival outcomes. Studies were excluded from the analysis as follow: (I) publications were position papers, editorials, case reports, comments, or review articles; (II) literature duplication based on an author or center; (III) research data was inappropriate or cannot be extracted; (IV) studies lacked control group for meta-analysis.

Data extraction

Two independent reviewers extracted predesigned data from the included studies. The extracted information was as follows: Basic characteristics of the study, including authors, country, patient inclusion criteria, sample size, design as well as quality assessment; Clinicopathological characteristics of patients, including gender, tumor location, differentiation, Lauren type, Borrmann classification, pTNM stage, and therapeutic regimens (involving chemotherapy, total/subtotal gastrectomy, curative resection, and lymphadenectomy); Survival outcomes, including metastasis, recurrence, and the short or long-term survival rates on different clinical tumor stage. The stage of gastric cancer was based on the American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) staging system. Lymphadenectomy was divided into D1 to D4, depending on the primary tumor location and removal of each lymph node station (32). Gastrectomy was defined as patients received surgery with or without D2 lymphadenectomy, while curative gastrectomy was defined as resection with D2 lymphadenectomy and a negative margin. The disagreement was resolved through discussion among the reviewers.

Quality assessment

The quality of the included studies was evaluated using The Newcastle-Ottawa Quality Assessment Scale (NOS) (33). The NOS checklist consisted of three major categories (selection, comparability, and outcome) with a maximum of nine stars. Each included study achieving six or more number of stars was graded high quality. Any disagreement was discussed to reach a consensus.

Statistical analysis

We conducted the review and meta-analysis using Revman software, version 5.3 (Cochrane Collaboration, Oxford, United Kingdom). Categorical variables were analyzed by the odds ratio (OR), while the corresponding 95% confidence interval (CI) was recorded. The Z test was conducted to determine the OR, with P<0.05 considered statistical significance. Heterogeneity was investigated using the χ2 test and the I2 test. If significant heterogeneity existed, we employed the random effect model; otherwise, the fixed effects model was adopted (34,35). Sensitivity analyses were undertaken to investigate sources of substantial heterogeneity.

Results

Studies selection

Our initial search strategy generated a total of 8,686 relevant clinical studies. After a screening of titles and abstracts, 108 articles were scrutinized by a full-text review. Eighty-three studies were eventually excluded by following the exclusion criteria and inclusion criteria. In total, the eligible 25 clinical studies (4,5,8-30) involving 81,188 gastric cancer patients were entered into the review and meta-analysis, of which one was a prospective study (17), three were multicenter studies (16,19,21), and the rest were all retrospective studies. showed the flow chart of the search process. The NOS scores and essential characteristics of the eligible studies were shown in .
Figure 1

The flow chart of the research process until December 2019.

Table 1

Basic characteristics of the included 25 studies

AuthorsCountryPatient criteriaDocument typeNOSGroupNo.AgeGenderTumor locationpTNM stage
MaleFemaleUpperMiddleLowerIIIIIIIV
Song et al. (4)ChinaGC underwent surgery (2007–2011)Retrospective Study7YG ≤40112–59531221645305918
OG ≥70358–274846164208258920638
Cormedi et al. (5)BrazilGC (2011–2013)Retrospective Study8YG ≤4071373437–––452336
OG >4022363.7413588–––35295289
Tavares et al. (8)PortugalGC with surgery (2000–2005)Retrospective Study7YG ≤4023–1211–––6646
OG >40360–207153–––764310597
Guan et al. (9)the United StatesGC (1973–2014)Retrospective Study8YG <351,369–7286413381332755159119385
OG ≥6546,521–28,10418,41711,8393,61712,2433,8383,4073,6044,358
Isobe et al. (10)JapanGAC (1977–2006)Retrospective Study8YG ≤4016934.5±4.8799034704068302348
OG >403,64964.5±10.02,5181,1317901,0471,3411,765471628782
Kim et al. (11)KoreaGC (1986–2000)Retrospective Study8YG ≤3513730.6±5.1637423505641213639
OG >7019473.3±3.113163164113060415538
Kunisaki et al. (12)JapanGC underwent curative surgery (1985–1999)Retrospective Study8YG ≤4013135.2±5.0646744651979162412
OG ≥5591860.2±3.2658260340386168510123174111
Liu et al. (13)ChinaGC underwent surgery; no chemotherapy; no metastasis. (2008–2014)Retrospective Study7YG ≤40198–11583–––––––
OG ≥551,096–895201–––––––
Okamoto et al. (14)JapanGC underwent laparotomy(1960–1984)Retrospective Study6YG <303424.910243137––––
OG ≥7513277.997351237663973155
Takatsu et al. (15)JapanGC underwent surgical resection (2000–2010)Retrospective Study8YG ≤4013636 [16–39]726425703565212822
OG ≥601,43565 [60–69]1,024411385581416786206253190
Tekesin et al. (16)TurkeyGC (1990–2014)Retrospective Cohort Study7YG ≤409236 [22–40]533917––541752
OG >4077460 [41–75]553221141–––2546195372
Wang et al. (17)ChinaGC underwent gastrectomy (1998–2006)Prospective Study7YG ≤402134.9±1.19121713––––
OG >553667.1±0.822144725119151
Hsieh et al. (18)JapanGAC underwent curative gastrectomy (1981–1992)Retrospective Study7YG ≤40115–466914276823225614
OG >601,009–62637319416062629316046789
Ma et al. (19)ChinaGC underwent curative surgery (2009–2011)Retrospective Study7YG ≤40125–7649–––302471–
OG >401,752–1,341411–––403400946–
Mitsudomi et al. (20)JapanGC (1970–1984)Retrospective Study7YG <40128–6662135831––––
OG ≥501,275–863412131379550––––
Kulig et al. (21)PolandGC (1977–1998)Retrospective Study6YG ≤4021435.01199524565624142563
OG >403,21761.02,277940387733677315251380770
Bani-Hani et al. (22)JordanGAC (1991–2001)Retrospective Study7YG ≤401736.3±0.97105334247
OG >4015963.8±0.71045526398311395546
Kim et al. (23)KoreaGC underwent surgery (1993–2000)Retrospective Study7YG ≤4017534.58±4.261007519678379204937
OG >401,12459.25±9.17765359120364624439145304236
Lai et al. (24)KoreaGC underwent curative surgery (1987–2004)Retrospective Study8YG ≤4088335476407125––44413521391
OG >406,07158.74,1951,876720––2,8501,0571,567597
Maehara et al. (25)JapanGC underwent surgery (1965–1991)Retrospective Study6YG <4017438.8±4.98985315863––––
OG >7035674.8±3.92471099086152––––
Silva et al. (26)BrazilGAC (1988–2005)Retrospective Study7YG ≤4062–38249–5021–35–
OG >40453–28816568–385127–280–
Zhou et al. (27)ChinaGC resections (2004–2014)Retrospective Study7YG ≤4015233.7±5.5453998577539326615
OG >4025062.9±10.4178727553115141355222
Adachi et al. (28)JapanGC underwent surgery (1981–1990)Retrospective Study7YG <4036–2016––616587
OG >6068–4325––2725131614
Bautista et al. (29)the United StatesNon-cardia GAC (2000–2010)Retrospective Cohort Study8YG <404634.1±4.1242211014––––
OG ≥501,20871.5±3.871449465379426––––
Wang et al. (30)ChinaGC underwent curative gastrectomy (2005–2010)Retrospective Study8YG ≤4034234.1±5.21981445379177829713726
OG >403,58861.4±10.12,4481,1408417411,7838769271,522263

No., number of patients; pTNM, pathological (p), primary tumor (T), lymph nodes (N) and distant metastases (M); GC, gastric cancer; GAC, gastric adenocarcinoma.

The flow chart of the research process until December 2019. No., number of patients; pTNM, pathological (p), primary tumor (T), lymph nodes (N) and distant metastases (M); GC, gastric cancer; GAC, gastric adenocarcinoma.

Clinicopathological characteristics

The clinicopathologic characteristics of the gastric cancer patients were presented in . Compared with the older group, younger patients with gastric cancer were more often female from pooled 25 studies (OR =2.09, 95% CI: 1.81–2.41, P<0.001, I2=76%) (). Younger patients were more likely to be a diffuse type (OR =4.29, 95% CI: 3.15–5.85, P<0.001, I2=82%), pTNM stage IV (OR =1.21, 95% CI: 1.08–1.35, P<0.001, I2=0), poorly differentiation (OR =3.59, 95% CI: 2.89–4.47, P<0.001, I2=82%), and a signet ring cell carcinoma (OR =4.81, 95% CI: 4.33–5.33, P<0.001, I2=0) ().
Table 2

Subgroup meta-analysis of clinicopathological characteristics and survival outcomes between the younger group and older group

SubgroupIncluded studiesIncluded patientsI2 (%)Effect modelOR/WMD95% CIP
Female2581,18876Random2.091.81–2.41<0.001
Diffuse type1056,33582Random4.293.15–5.85<0.001
pTNM stage IV1626,2020Fixed1.211.08–1.35<0.001
Poorly differentiation1975,34982Random3.592.89–4.47<0.001
SRCC552,2620Fixed4.814.33– 5.33<0.001
Therapeutic regimen
   Subtotal gastrectomy914,42739Fixed0.880.79–0.990.03
   Curative gastrectomy1418,15910Fixed0.930.82–1.060.30
   D1 lymphadenectomy47,38725Fixed0.590.48–0.73<0.001
   ≥ D2 lymphadenectomy47,38727Fixed1.771.44–2.18<0.001
   Chemotherapy68,75043Fixed1.791.49–2.16<0.001
   Postoperative complications56,30973Random0.440.24–0.790.006
Recurrence/metastasis
   Peritoneal recurrence41,96511Fixed1.931.31–2.840.001
   Lymph node metastasis83,9010Fixed0.830.69–0.980.03
   Hepatic metastasis911,1260Fixed0.680.47–0.980.04
   Peritoneal metastasis911,69563Random1.631.16–2.270.004
5-year OS959,64760Random1.010.79–1.300.92
5-year OS underwent surgery1826,77056Random1.351.16–1.57<0.001
   Stage I-OS86,53611Fixed2.381.56–3.61<0.001
   Stage II-OS83,34746Fixed1.280.98–1.660.07
   Stage III-OS75,70227Fixed1.361.14–1.63<0.001
   Stage IV-OS71,4830Fixed1.931.30–2.850.001
5-year OS underwent curative surgery1219,01260Random1.391.12–1.720.002
   Stage I-OS45,26151Random1.730.86–3.490.13
   Stage II-OS42,77151Random0.950.60–1.510.83
   Stage III-OS44,6390Fixed1.291.05–1.580.01
   Stage IV-OS31,0160Fixed1.861.20–2.890.006

pTNM, pathological (p), primary tumor (T), lymph nodes (N) and distant metastases (M); SRCC, signet ring cell carcinoma; OS, overall survival.

Table S1

Clinicopathological characteristics of the included 25 studies

AuthorsGroupNo.Tumor size ± SD (cm)PainBleedingCardiopulmonary diseaseDifferentiationSRCCMucinousLauren typeBorrmann classification
WellPoorIntestinalDiffuseMixedIIIIIIIV
Song et al. (4)YG112≤6 n=70; >6 n=42–––6106–––––––––
OG358≤6 n=239; >6 n=119–––83275–––––––––
Cormedi et al. (5)YG71––––––––3573––––
OG223––––––––787414––––
Tavares et al. (8)YG23–123–412––8150––––
OG360–160100–5689––2551050––––
Guan et al. (9)YG1,3695.00±3.00–––3191655825668652–––––
OG46,5214.00±1.47–––249322,616575699037,7997,021–––––
Isobe et al. (10)YG169–––––66754–––––––
OG3,649–––––94360082–––––––
Kim et al. (11)YG1375.07±3.23–––––254–––5139326
OG1945.16±3.45–––––610–––104312813
Kunisaki et al. (12)YG131<5 n=76; ≥5 n=55–––30101–––––––––
OG918<5 n=536; ≥5 n=382–––479439–––––––––
Liu et al. (13)YG198–––07164–––––––––
OG1,096–––29123587–––––––––
Okamoto et al. (14)YG34–––––2220–––0/200124
OG132–––––5115–––3/85253414
Takatsu et al. (15)YG136––––13123–––––––––
OG1,435––––662773–––––––––
Tekesin et al. (16)YG92–226–––––39457––––
OG774–19152–––––52622021––––
Wang et al. (17)YG21<5 n=13; ≥5 n=8–––41041–––16122
OG36<5 n=23; ≥5 n=13–––10425–––213191
Hsieh et al. (18)YG1154.80±3.50–––1798––176413––––
OG1,0094.50±3.00–––453556––491279103––––
Ma et al. (19)YG125––––3111–––––––––
OG1,752––––931,228–––––––––
Mitsudomi et al. (20)YG128–4863594–––––2112820
OG1,275–20314600449–––––20175347106
Kulig et al. (21)YG214–90122––––428018––––
OG3,217–1831186293––––1,106623207––––
Bani-Hani et al. (22)YG17–122––8––611–––––
OG159–10923––41––12118–––––
Kim et al. (23)YG175––––42133–––––––––
OG1,124––––608516–––––––––
Lai et al. (24)YG883≤4 n=586; >4 n=288–––135711–––––1011429775
OG6,071≤4 n=354; >4 n=2,488–––2,6613,232–––––6658122,039405
Maehara et al. (25)YG1747.10±4.20–––39135–––––––––
OG3566.30±3.80–––225129–––––––––
Silva et al. (26)YG62≤5 n=31; >5 n=27–––––––153611––––
OG453≤5 n=179; >5 n=259–––––––23014677––––
Zhou et al. (27)YG152–7319–––––1412018––––
OG250–9811–––––1567321––––
Adachi et al. (28)YG36623–0–33–––––––––
OG686.0516–21–35–––––––––
Bautista et al. (29)YG46–––3037––1432–––––
OG1,208–––56440759––754494–––––
Wang et al. (30)YG342––––162588616641661121811415654
OG3,588––––1722,2445342337902,0491,0272721,2521,756308

No., number of patients; Pain, abdominal pain; SRCC, signet ring cell carcinoma; YG, younger group; OG, older group.

Figure S1

Meta-analysis of female ratio between younger and older group.

Figure S2

The proportion of clinicopathologic feature between younger and older group. (A) Meta-analysis of diffuse type; (B) meta-analysis of pTNM stage IV; (C) meta-analysis of poorly differentiation; (D) meta-analysis of signet ring cell carcinoma.

pTNM, pathological (p), primary tumor (T), lymph nodes (N) and distant metastases (M); SRCC, signet ring cell carcinoma; OS, overall survival. Concerning to therapeutic regimen, six studies showed that younger group had a higher chemotherapy rate when compared to older group (OR =1.79, 95% CI: 1.49–2.16, P<0.001, I2=43%). In addition, the proportions of younger patients underwent subtotal gastrectomy or D1 resection were significantly lower than those of the older (OR =0.88, 95% CI: 0.79–0.99, P=0.03, I2=39%; OR =0.59, 95% CI: 0.48–0.73, P<0.001, I2=25%, respectively). However, there were no statistical differences in curative resection rate between the two groups (OR =0.93; 95% CI: 0.82–1.06, P=0.30, I2=10%) ().
Figure S3

The proportion of therapeutic regimen between younger and older group. (A) Meta-analysis of subtotal gastrectomy; (B) meta-analysis of D1 lymphadenectomy; (C) meta-analysis of chemotherapy; (D) meta-analysis of curative resection.

Postoperative complications

A total of 6,309 patients from five studies were enrolled in postoperative complications. The result revealed that the proportion of complications in younger patients was significantly lower compared to the older (OR =0.44, 95% CI: 0.24–0.79, P=0.006), and the heterogeneity between the younger and older group was significant (I2=73%) ().
Figure S4

Meta-analysis of the proportion of postoperative complications between younger and older group.

Survival outcomes

presented the meta-analysis of the 5-year overall survival (OS) with total patients, gastrectomy group, and only curative gastrectomy group, respectively. There was no significant difference for total patients based on the nine included studies (OR =1.01, 95% CI: 0.79–1.30, P=0.92, I2=60%). However, the pooled 18 and 12 studies respectively showed that younger adults in gastrectomy group and only curative gastrectomy group were associated with better survival relative to that of the older (OR =1.35, 95% CI: 1.16–1.57, P<0.001, I2=56%; OR =1.39, 95% CI: 1.12–1.72, P=0.002, I2=60%).
Figure 2

The 5-year overall survival for gastric cancer between younger and older group. (A) The 5-year overall survival of total patients; (B) the 5-year overall survival of patients underwent gastrectomy; (C) the 5-year overall survival of patients underwent curative gastrectomy.

The 5-year overall survival for gastric cancer between younger and older group. (A) The 5-year overall survival of total patients; (B) the 5-year overall survival of patients underwent gastrectomy; (C) the 5-year overall survival of patients underwent curative gastrectomy. Moreover, further survival analyses between younger and older patients were done under the different pTNM tumor stage. Four of the studies provided survival rates for gastrectomy group, and the meta-analysis showed that younger patients at pTNM stage I, stage III, and stage IV were associated with better 5-year OS than older (OR =2.38, 95% CI: 1.56–3.61, P<0.001, I2=11%; OR =1.36, 95% CI: 1.14–1.63, P<0.001, I2=27%; OR =1.93, 95% CI: 1.30–2.85, P=0.001, I2=0%, respectively) (). For the only curative gastrectomy group, three of the included studies revealed that younger patients at pTNM stage III and stage IV also had improved survival (OR =1.29, 95% CI: 1.05–1.58, P=0.01, I2=0%; OR =1.86, 95% CI: 1.20–2.89, P=0.006, I2=0%, respectively), but there was no statistical difference in gastric cancer at stage I (OR =1.73, 95% CI: 0.86–3.49, P=0.13, I2=51%) (). The short-term (including the 1-, 2-, 3-year) survival rates were presented in .
Figure 3

The 5-year overall survival of gastric cancer underwent gastrectomy between younger and older group. (A) Meta-analysis of patients at pTNM stage I; (B) meta-analysis of patients at pTNM stage II; (C) meta-analysis of patients at pTNM stage III; (D) meta-analysis of patients at pTNM stage IV.

Figure 4

The 5-year overall survival of gastric cancer underwent curative gastrectomy between younger and older group. (A) Meta-analysis of patients at pTNM stage I. (B) meta-analysis of patients at pTNM stage II; (C) meta-analysis of patients at pTNM stage III; (D) meta-analysis of patients at pTNM stage IV.

Table S2

Subgroup meta-analysis of overall survival comparison between the younger group and older group

SubgroupIncluded studiesIncluded patientsI2 (%)Effect modelOR/WMD95% CIP
OS
   1-year OS859,13281Random1.080.80–1.450.63
   2-year OS859,13278Random1.040.79–1.360.79
   3-year OS859,13274Random1.010.78–1.320.93
   5-year OS959,64760Random1.010.79–1.300.92
OS underwent gastrectomy
   1-year OS1518,4420Fixed1.201.04–1.390.01
   2-year OS1518,44256Random1.311.08–1.580.005
   3-year OS1518,4421Fixed1.331.19–1.48<0.001
   5-year OS1826,77056Random1.351.16–1.57<0.001
Stage I-OS underwent gastrectomy1
   1-year OS55,4370Fixed5.181.03–26.030.05
   2-year OS55,4370Fixed2.291.11–4.710.02
   3-year OS55,4370Fixed3.321.72–6.40<0.001
   5-year OS86,53611Fixed2.381.56–3.61<0.001
Stage II-OS underwent gastrectomy
   1-year OS52,7350Fixed1.540.72–3.330.27
   2-year OS52,7350Fixed1.250.80–1.940.33
   3-year OS52,73545Fixed1.471.01–2.140.04
   5-year OS83,34746Fixed1.280.98–1.660.07
Stage III-OS underwent gastrectomy
   1-year OS54,49961Random1.410.81–2.450.22
   2-year OS54,49955Random1.531.07–2.200.02
   3-year OS54,49960Random1.621.14–2.310.007
   5-year OS75,70227Fixed1.361.14–1.63<0.001
Stage IV-OS underwent gastrectomy
   1-year OS51,34174Random1.180.54–2.580.68
   2-year OS51,34183Random3.461.26–9.560.02
   3-year OS51,34141Fixed1.771.23–2.540.002
   5-year OS71,4830Fixed1.931.30–2.850.001
OS underwent curative surgery
   1-year OS1112,6600Fixed1.351.05–1.720.02
   2-year OS1112,66033Fixed1.221.03–1.450.02
   3-year OS1112,6600Fixed1.361.17–1.58<0.001
   5-year OS1219,01260Random1.391.12–1.720.002
Stage I-OS underwent curative surgery
   5-year OS45,26151Random1.730.86–3.490.13
Stage II-OS underwent curative surgery
   5-year OS42,77151Random1.070.80–1.430.67
Stage III-OS underwent curative surgery
   5-year OS44,6390Fixed1.291.05–1.580.01
Stage IV-OS underwent curative surgery
   5-year OS31,0160Fixed1.861.20–2.890.006
OS underwent Non-curative surgery
   1-year OS326870Random1.310.40–4.290.66
   2-year OS326838Fixed0.920.49–1.710.87
   3-year OS32680Fixed1.370.72–2.610.34
   5-year OS32680Fixed1.140.56–2.360.72

1stage, pTNM stage. OS, overall survival.

The 5-year overall survival of gastric cancer underwent gastrectomy between younger and older group. (A) Meta-analysis of patients at pTNM stage I; (B) meta-analysis of patients at pTNM stage II; (C) meta-analysis of patients at pTNM stage III; (D) meta-analysis of patients at pTNM stage IV. The 5-year overall survival of gastric cancer underwent curative gastrectomy between younger and older group. (A) Meta-analysis of patients at pTNM stage I. (B) meta-analysis of patients at pTNM stage II; (C) meta-analysis of patients at pTNM stage III; (D) meta-analysis of patients at pTNM stage IV. Concerning to the metastasis status of gastric cancer, nine of the 25 studies showed that younger group was predominant in peritoneal metastasis (OR =1.63, 95% CI: 1.16–2.27, P=0.004, I2=63%). Some included studies reported the lymph node metastasis and hepatic metastasis of gastric cancer, and our result showed that both lymph node metastasis and hepatic metastasis ratio was lower in younger group compared with those of the older (OR =0.83, 95% CI: 0.69–0.98, P=0.03, I2=0%; OR =0.68, 95% CI: 0.47–0.98, P=0.04, I2=0%). In addition, 4 related studies indicated that the incidence of peritoneal recurrence was significantly higher in younger group (OR =1.93, 95% CI: 1.31–2.84, P=0.001, I2=11%) ( and ).
Figure S5

The proportion of metastasis and recurrence between younger and older group. (A) Meta-analysis of peritoneal recurrence; (B) meta-analysis of peritoneal metastasis; (C) meta-analysis of lymph node metastasis; (D) meta-analysis of hepatic metastasis.

Table S3

Therapeutic regimens and survival outcomes of the included studies

AuthorsGroupNo.Type of gastrectomyResection marginLymphadenectomyChemotherapyComplicationPeritoneal recurrenceMetastasis
SubtotalTotalR0R1/R2D0D1≥D2Lymph nodeVesselHepaticPeritoneal
Song et al. (4)YG112––8527––––––––––
OG358––26098––––––––––
Cormedi et al. (5)YG71–––––––21––––––
OG223–––––––59––––––
Tavares et al. (8)YG23419–––––9–3––1–
OG360133227–––––86–10––21–
Guan et al. (9)YG1,349––––––––––––––
OG46,521––––––––––––––
Isobe et al. (10)YG169–52112–33011969––––433
OG3,649–9362,728–2179882,2051,180––––203414
Kim et al. (11)YG1377847101–––––––70–521
OG19412252157–––––––106–618
Kunisaki et al. (12)YG1319325121––24107––18483426
OG918644274827––280638––613973322244
Liu et al. (13)YG–––––––––––––––
OG–––––––––––––––
Okamoto et al. (14)YG34––15–10–––––19–213
OG132––73–23–––––64–1020
Takatsu et al. (15)YG126–3211422––––146––1/114–
OG1,435–4451,241194––––27658––33/1,241–
Tekesin et al. (16)YG921732–––––––––29–26
OG774185260–––––––––254–230
Wang et al. (17)YG21––19–––––4––20–76
OG36––33–––––153––155–461
Hsieh et al. (18)YG115843110114–––82––12–––
OG1,009753256893116–––590––25–––
Ma et al. (19)YG125–––––––96–––43––
OG1,752–––––––1,023–––451––
Mitsudomi et al. (20)YG1281329103–––––9–––––
OG1,275902361,076–––––15–––––
Kulig et al. (21)YG21489637874–39113–65–––––
OG3,2171,1958981,146947–6411,452–1,058–––––
Bani-Hani et al. (22)YG17––7–––––––––––
OG159––66–––––––––––
Kim et al. (23)YG175––14431––––––86–––
OG1,124––888236––––––566–––
Lai et al. (24)YG883612262––––––––––––
OG6,0714,4911,519––––––––––––
Maehara et al. (25)YG17411262125––32141––159515223
OG356212139255––119237––25207811623
Silva et al. (26)YG–––––––––––38–––
OG–––––––––––342–––
Adachi et al. (28)YG236––––––––7–17–1/74/7
OG368––––––––25–33–3/247/24
Bautista et al. (29)YG46–––––––31––––––
OG1,208–––––––475––––––
Wang et al. (30)YG342––32715–––267––––1613
OG3,588––3,406182–––2,856––––165173

No., number of patients; YG, younger group; OG, older group; R, resection margin.

Discussion

The review and meta-analysis involved 24 retrospective comparative trails and one prospective study with 81,188 patients with gastric cancer. Our findings demonstrated that the younger group after gastrectomy or only curative gastrectomy was correlated with a better OS, but there was no significant difference for total patients between the two groups. To our best knowledge, this analysis was the most extensive evaluation to compare the clinicopathological feature and prognosis between the younger and older group. Several findings regarding the clinicopathological characteristics in the meta-analysis were in agreement with previous researches, including a higher proportion of female, poorly differentiation, signet ring cell carcinoma, diffuse histology, and pTNM tumor stage IV in younger adults (8-21). Our survey revealed that younger patients had a higher proportion of females, while male predominance was mostly seen in the older group. Although the reasons for female predominance in younger patients were not clear, some potential explanations had been identified. Several studies considered hormonal factors, such as estrogens and higher percentages of estrogen receptor-positive cells might be associated with the predominance of younger females (36,37). Compared to older patients, younger patients with gastric cancer had been believed to be related to genetic changes rather than environmental factors (38). Thereby more frequent exposure to environmental carcinogens, such as cigarettes, might lead to the dominance among older male patients (39). Concerning to histological type, our analysis revealed that poorly differentiation, diffuse-type, and signet ring cell carcinoma were predominant in the younger group. In comparison, more patients in the older group were diagnosed as intestinal type and mucous adenocarcinoma. The primary reason may be germline mutations, specifically in the CDH1 gene, as reported in some researches (26,40,41). While the included studies rarely capture the duration of symptoms before initial diagnosis, other researches have reported delayed diagnosis, and hereditary factors may be closely correlated with advanced gastric cancer (42,43). Surgery, especially curative resection, was an important approach for patients with gastric cancer (44). There were higher proportions of chemotherapy and ≥ D2 lymphadenectomy in the younger group compared with the older. However, the percentages of total gastrectomy and curative resection revealed no statistical differences between younger and older groups, while subtotal gastrectomy was frequently performed in older patients. These results may be due to the significant comorbidities and impairment of functional status in older patients (45-47). Moreover, a previous study demonstrated that the ratio of older patients who had other synchronous or previous malignancies at initial diagnosis was up to 21% based on Munich Cancer Registry data (48). In our review, postoperative complications were more prevalent in the older group, which also reflected a worse tolerance for surgery or chemotherapy. Several studies investigated that the incidence of postoperative complications was closely correlated with poor prognosis (49,50), thus providing a survival advantage for the younger group. In this analysis, a tendency of peritoneal metastasis in the younger group may reflect the genetic susceptibility, such as CDH1 and RhoA, that could lead to more aggressive biological behaviors (40,51). Moreover, the infiltration of poorly differentiated gastric cancer was more pronounced in the vertical direction, thus conferring lymph node involvement and peritoneal dissemination. Metastasis was the leading cause of recurrence, and it had been thought that peritoneal metastasis was the most common form of repetition in gastric carcinoma (15). Our finding indicated a higher incidence of peritoneal recurrence in younger patients, which was similar to the other conclusion (12). Younger gastric cancer patients as a group revealed similar long-term OS compared to older, and this finding was consistent with previous studies (5,10,11,20). In the subgroups of gastrectomy and only curative gastrectomy, both the short-term (including the 1-, 2-, 3-year) and long-term (including the 5-year) OS for older group was more miserable than those of the younger group, possibly due to a more significant percentage of comorbidities and complications. When the 5-year OS under different pTNM stages was evaluated, the results differed substantially between the younger and older group. A trend towards better long-term survival in the younger group may reflect a higher tolerance for the patients given a younger age and fewer comorbidities. Moreover, the shorter life expectancy of the older group compared to the younger may also be responsible. There were several limitations in the analysis because of the characteristics of the included studies identified. Firstly, only one of the trials we identified was a prospective study. Secondly, most of the included studies were from Eastern Asia, which might not have a great representative and guiding value across the globe, especially in Western countries. Thereby, more related researches were expected to evaluate in gastric cancer patients at a younger age. Thirdly, there were inevitable heterogeneities, such as female ratio, diffuse type, as well as several survival variables in the analysis. The contribution of each included study to the pooled estimate was evaluated in the sensitivity analyses, and the result showed that sources of these heterogeneities were mainly from the selection bias. Furthermore, the lack of available patient data did not allow our analysis to assess disease-specific survival and disease-free survival. Despite these limitations, the study to our knowledge was the most extensive analysis evaluating the clinicopathological characteristics and survival outcomes in the younger and older patients, which may overcome the limitation of small sample size and single-institution targeted the field. Besides, all of the clinical studies involved in the meta-analysis had a high quality and met our inclusion criteria, thus might provide more valuable resources for the clinicians in patients' management and decision-making.

Conclusions

In conclusion, younger patients with gastric cancer were more often diagnosed as poorly differentiation and later pTNM tumor stage. However, younger cancer patients following gastrectomy had a better OS rate than patients in older group. Future large-scale analyses are expected to confirm our findings.
  51 in total

1.  Limited operation for gastric cancer in the elderly.

Authors:  S Tsujitani; K Katano; A Oka; M Ikeguchi; M Maeta; N Kaibara
Journal:  Br J Surg       Date:  1996-06       Impact factor: 6.939

2.  Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations.

Authors:  D G Huntsman; F Carneiro; F R Lewis; P M MacLeod; A Hayashi; K G Monaghan; R Maung; R Seruca; C E Jackson; C Caldas
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

3.  Clinicopathological features of gastric cancer in young patients.

Authors:  Yukiko Takatsu; Naoki Hiki; Souya Nunobe; Manabu Ohashi; Michitaka Honda; Toshiharu Yamaguchi; Toshifusa Nakajima; Takeshi Sano
Journal:  Gastric Cancer       Date:  2015-03-10       Impact factor: 7.370

4.  Clinicopathological characteristics, prognosis and survival outcome of gastric cancer in young patients: A large cohort retrospective study.

Authors:  Kemal Tekesin; Mehmet Emin Gunes; Deniz Tural; Emre Akar; Alisan Zirtiloglu; Mustafa Karaca; Fatih Selcukbiricik; Savas Bayrak; Ahmet Ozet
Journal:  J BUON       Date:  2019 Mar-Apr       Impact factor: 2.533

5.  Clinicopathological features and prognostic factors of gastric cancer patients aged 40 years or younger.

Authors:  Feng-Jen Hsieh; Yu-Chao Wang; Jun-Te Hsu; Keng-Hao Liu; Chun-Nan Yeh
Journal:  J Surg Oncol       Date:  2012-03       Impact factor: 3.454

6.  Outcome of gastric cancer in the elderly: a population-based evaluation of the Munich Cancer Registry.

Authors:  Anne Schlesinger-Raab; André L Mihaljevic; Silvia Egert; Rebecca Emeny; Karl-Walter Jauch; Jörg Kleeff; Alexander Novotny; Natascha C Nüssler; Miriam Rottmann; Wolfgang Schepp; Wolfgang Schmitt; Gabriele Schubert-Fritschle; Bernhard Weber; Christoph Schuhmacher; Jutta Engel
Journal:  Gastric Cancer       Date:  2015-08-11       Impact factor: 7.370

7.  A clinicopathologic study of gastric carcinoma with reference to age of patients.

Authors:  Y Adachi; Y Ogawa; Y Sasaki; H Yukaya; M Mori; K Sugimachi
Journal:  J Clin Gastroenterol       Date:  1994-06       Impact factor: 3.062

8.  The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma.

Authors:  Nabil P Rizk; Peter B Bach; Deborah Schrag; Manjit S Bains; Alan D Turnbull; Martin Karpeh; Murray F Brennan; Valerie W Rusch
Journal:  J Am Coll Surg       Date:  2004-01       Impact factor: 6.113

9.  Meta-analysis in clinical trials revisited.

Authors:  Rebecca DerSimonian; Nan Laird
Journal:  Contemp Clin Trials       Date:  2015-09-04       Impact factor: 2.226

10.  Clinicopathological features and prognosis of gastric cancer in young patients.

Authors:  Shushang Liu; Fan Feng; Guanghui Xu; Zhen Liu; Yangzi Tian; Man Guo; Xiao Lian; Lei Cai; Daiming Fan; Hongwei Zhang
Journal:  BMC Cancer       Date:  2016-07-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.